Switch theme
Sign up to access all valuation multiples
Inner Mongolia Furui Medical Science Co Ltd is a China based medical service platform company. It provides disease diagnosis, drug treatment and chronic disease management centered on the liver disease field. The product portfolio of the company includes tablets, capsules, and plaster. In addition, the company is also engaged in providing health-care services.
1998
330
LTM Revenue $206M
Last FY EBITDA $50.6M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Inner Mongolia Furui Medical Science has a last 12-month revenue (LTM) of $206M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Inner Mongolia Furui Medical Science achieved revenue of $187M and an EBITDA of $50.6M.
Inner Mongolia Furui Medical Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Inner Mongolia Furui Medical Science valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $206M | XXX | $187M | XXX | XXX | XXX |
| Gross Profit | $155M | XXX | $139M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $50.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 27% | XXX | XXX | XXX |
| EBIT | $46.6M | XXX | $42.9M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $20.3M | XXX | $15.7M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Inner Mongolia Furui Medical Science's stock price is CNY 35 (or $5).
Inner Mongolia Furui Medical Science has current market cap of CNY 9.4B (or $1.3B), and EV of CNY 8.8B (or $1.2B).
See Inner Mongolia Furui Medical Science trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.3B | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Inner Mongolia Furui Medical Science has market cap of $1.3B and EV of $1.2B.
Inner Mongolia Furui Medical Science's trades at 6.5x EV/Revenue multiple, and 24.0x EV/EBITDA.
Equity research analysts estimate Inner Mongolia Furui Medical Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inner Mongolia Furui Medical Science has a P/E ratio of 64.4x.
See valuation multiples for Inner Mongolia Furui Medical Science and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 24.0x | XXX | XXX | XXX |
| EV/EBIT | 26.1x | XXX | 28.4x | XXX | XXX | XXX |
| EV/Gross Profit | 7.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 64.4x | XXX | 83.1x | XXX | XXX | XXX |
| EV/FCF | 27.1x | XXX | 3586.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInner Mongolia Furui Medical Science's last 12 month revenue growth is 23%
Inner Mongolia Furui Medical Science's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Inner Mongolia Furui Medical Science's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Inner Mongolia Furui Medical Science's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Inner Mongolia Furui Medical Science and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 50% | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inner Mongolia Furui Medical Science acquired XXX companies to date.
Last acquisition by Inner Mongolia Furui Medical Science was XXXXXXXX, XXXXX XXXXX XXXXXX . Inner Mongolia Furui Medical Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Inner Mongolia Furui Medical Science founded? | Inner Mongolia Furui Medical Science was founded in 1998. |
| Where is Inner Mongolia Furui Medical Science headquartered? | Inner Mongolia Furui Medical Science is headquartered in China. |
| How many employees does Inner Mongolia Furui Medical Science have? | As of today, Inner Mongolia Furui Medical Science has 330 employees. |
| Is Inner Mongolia Furui Medical Science publicy listed? | Yes, Inner Mongolia Furui Medical Science is a public company listed on SHE. |
| What is the stock symbol of Inner Mongolia Furui Medical Science? | Inner Mongolia Furui Medical Science trades under 300049 ticker. |
| When did Inner Mongolia Furui Medical Science go public? | Inner Mongolia Furui Medical Science went public in 2010. |
| Who are competitors of Inner Mongolia Furui Medical Science? | Similar companies to Inner Mongolia Furui Medical Science include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Inner Mongolia Furui Medical Science? | Inner Mongolia Furui Medical Science's current market cap is $1.3B |
| What is the current revenue of Inner Mongolia Furui Medical Science? | Inner Mongolia Furui Medical Science's last 12 months revenue is $206M. |
| What is the current revenue growth of Inner Mongolia Furui Medical Science? | Inner Mongolia Furui Medical Science revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Inner Mongolia Furui Medical Science? | Current revenue multiple of Inner Mongolia Furui Medical Science is 5.9x. |
| Is Inner Mongolia Furui Medical Science profitable? | Yes, Inner Mongolia Furui Medical Science is EBITDA-positive (as of the last 12 months). |
| What is the current FCF of Inner Mongolia Furui Medical Science? | Inner Mongolia Furui Medical Science's last 12 months FCF is $44.8M. |
| What is Inner Mongolia Furui Medical Science's FCF margin? | Inner Mongolia Furui Medical Science's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of Inner Mongolia Furui Medical Science? | Current FCF multiple of Inner Mongolia Furui Medical Science is 27.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
